{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "9387908",
  "DateCompleted": {
    "Year": "1998",
    "Month": "01",
    "Day": "27"
  },
  "DateRevised": {
    "Year": "2013",
    "Month": "11",
    "Day": "21"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "eng"
    ],
    "ELocationID": [],
    "Journal": {
      "ISSN": "0392-9078",
      "JournalIssue": {
        "Volume": "16",
        "Issue": "3",
        "PubDate": {
          "Year": "1997",
          "Month": "Sep"
        }
      },
      "Title": "Journal of experimental & clinical cancer research : CR",
      "ISOAbbreviation": "J Exp Clin Cancer Res"
    },
    "ArticleTitle": "Triple combination antimicrobial regimen in the treatment of infections of neutropenic cancer patients.",
    "Pagination": {
      "StartPage": "321",
      "EndPage": "324",
      "MedlinePgn": "321-4"
    },
    "Abstract": {
      "AbstractText": [
        "Twenty-six cancer patients (pts) with chemotherapy-related neutropenic fever were treated with vancomycin 30 mg/m2/day i.v. every 12 hrs, imipenem 1500 mg/day i.v. every 8 hrs, and pefloxacin 800 mg/day i.v. every 12 hrs. Twelve fevers of unknown origin (FUO), 10 gram-positive, 3 gram-negative and 1 mycoplasma were also treated. Globally, cure was observed in 22 pts (84%) and failure in 4 pts (16%); in gram-positive infections alone, cure was observed in 10 pts (80%) and failure in 4 pts (20%). Defervescence was obtained within 3 days in 77% pts. No relevant side effects were observed."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Regina Elena Institute for Cancer Research, Rome, Italy."
          }
        ],
        "LastName": "Casali",
        "ForeName": "A",
        "Initials": "A"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Santini",
        "ForeName": "S",
        "Initials": "S"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Della Giulia",
        "ForeName": "M",
        "Initials": "M"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Di Lauro",
        "ForeName": "L",
        "Initials": "L"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Vici",
        "ForeName": "P",
        "Initials": "P"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Gionfra",
        "ForeName": "T",
        "Initials": "T"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Sega",
        "ForeName": "F M",
        "Initials": "FM"
      }
    ],
    "PublicationTypeList": [
      "Clinical Trial",
      "Journal Article"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "England",
    "MedlineTA": "J Exp Clin Cancer Res",
    "NlmUniqueID": "8308647",
    "ISSNLinking": "0392-9078"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Anti-Bacterial Agents"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Anti-Infective Agents"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Antineoplastic Agents"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Thienamycins"
    },
    {
      "RegistryNumber": "2H52Z9F2Q5",
      "NameOfSubstance": "Pefloxacin"
    },
    {
      "RegistryNumber": "6Q205EH1VU",
      "NameOfSubstance": "Vancomycin"
    },
    {
      "RegistryNumber": "71OTZ9ZE0A",
      "NameOfSubstance": "Imipenem"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Anti-Bacterial Agents"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Anti-Infective Agents"
    },
    {
      "QualifierName": [
        "adverse effects",
        "therapeutic use"
      ],
      "DescriptorName": "Antineoplastic Agents"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Drug Therapy, Combination"
    },
    {
      "QualifierName": [
        "drug therapy",
        "etiology"
      ],
      "DescriptorName": "Fever"
    },
    {
      "QualifierName": [
        "drug therapy",
        "etiology"
      ],
      "DescriptorName": "Gram-Negative Bacterial Infections"
    },
    {
      "QualifierName": [
        "drug therapy",
        "etiology"
      ],
      "DescriptorName": "Gram-Positive Bacterial Infections"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Imipenem"
    },
    {
      "QualifierName": [
        "drug therapy",
        "etiology"
      ],
      "DescriptorName": "Mycoplasma Infections"
    },
    {
      "QualifierName": [
        "complications",
        "drug therapy",
        "microbiology"
      ],
      "DescriptorName": "Neoplasms"
    },
    {
      "QualifierName": [
        "chemically induced",
        "drug therapy",
        "microbiology"
      ],
      "DescriptorName": "Neutropenia"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Pefloxacin"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Thienamycins"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Vancomycin"
    }
  ]
}